SCHEDULE: Akari Therapeutics: Patel Boosts Stake to 10.4%

Samir R. Patel and PranaBio Investments LLC have increased their beneficial ownership in Akari Therapeutics Plc to 10.4% following a private placement.

Summary

• Samir R. Patel and PranaBio Investments LLC now beneficially own an aggregate of 9,725,215,000 Ordinary Shares of Akari Therapeutics Plc, representing 10.4% of the outstanding shares.
• This ownership includes 285,336,000 shares held directly by Dr. Patel, 6,062,010,000 shares held by PranaBio, 1,579,785,000 options exercisable within 60 days of March 1, 2026, granted to Dr. Patel, and 1,798,084,000 shares underlying prefunded warrants exercisable within 60 days of March 1, 2026, to PranaBio.
• The increase in ownership resulted from a private placement closed on December 17, 2025, where Dr. Patel purchased 618,658 Series G Warrants and 618,658 Pre-Funded Warrants.
• Additionally, Dr. Patel purchased 231,997 Note Exchange Warrants and 231,997 Pre-Funded Warrants in the same private placement.
• The combined price for these warrants was $0.4041 per Series G Warrant and Pre-Funded Warrant pair, and per Note Exchange Warrant and Pre-Funded Warrant pair.
• The funds used by Dr. Patel for these acquisitions were from his personal funds.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. An insider increasing their stake, especially with personal funds, often signals confidence in the company's prospects, which can be reassuring to other investors.

Positives

• A key insider, Dr. Samir R. Patel, has increased his stake in Akari Therapeutics Plc, signaling confidence in the company's future prospects.
• The investment was made using Dr. Patel's personal funds, indicating a strong personal commitment to the company.
• The private placement provided capital to Akari Therapeutics Plc, which can support its operations and strategic initiatives.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company regarding its future operations or financial performance, focusing instead on changes in beneficial ownership.

Industry Context

StockSavvy.ai notes that an increase in insider ownership, particularly by a significant shareholder like Dr. Patel, can often be interpreted positively by the market, suggesting confidence in the company's strategic direction or undervaluation. In the biotechnology sector, such investments can be crucial for funding research and development, especially for smaller firms like Akari Therapeutics Plc.

Related Party Transactions

• Dr. Samir R. Patel, a reporting person and manager of PranaBio Investments LLC, participated in a private placement of Akari Therapeutics Plc's securities.
• This transaction involved the purchase of warrants from the Issuer by Dr. Patel using personal funds.

Stakeholder Impact

• Shareholders: The increased insider ownership by Dr. Patel could be perceived as a positive signal, potentially boosting investor confidence.
• Company (Akari Therapeutics Plc): The private placement provided capital to the company, which can support its operations and strategic initiatives.

Key Dates

Recommendation

While the increased insider stake by Dr. Patel is a positive signal of confidence, this filing primarily reports an ownership change rather than new operational or financial performance data. Without further information on the company's strategic direction, financial health, or pipeline developments, a 'hold' recommendation is prudent, acknowledging the positive insider action while awaiting more comprehensive company updates.

Keywords

Akari Therapeutics, AKTX, Samir R. Patel, PranaBio Investments, Beneficial Ownership, Private Placement, Warrants, Biotechnology, Pharmaceuticals, Insider Buying